Laboratory of Chronic Airway Infection, Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Laboratory of Chronic Airway Infection, Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Res Microbiol. 2020 Jul-Sep;171(5-6):211-214. doi: 10.1016/j.resmic.2020.03.001. Epub 2020 Mar 18.
Mycobacterium abscessus (MAB) comprise rapidly growing, often multidrug-resistant (MDR), nontuberculous mycobacteria responsible for pulmonary and other infections in susceptible hosts. Antimicrobial peptides (APs) are natural and synthetic antimicrobials active against a range of microorganisms including mycobacteria. We evaluated APs activity against MAB reference and clinical strains. We observed minimal inhibitory concentrations of 1.6 to >50 μg/mL. Further work with the most active AP demonstrated protection of Acanthamoeba castellanii (AC) from killing by ingested MAB including MDR MAB strains. Antimicrobial peptides offer an attractive potential option for treatment of drug resistant treatment-refractory MAB.
脓肿分枝杆菌（MAB）是一种快速生长的、常为多药耐药（MDR）的非结核分枝杆菌，可导致易感宿主发生肺部和其他部位的感染。抗菌肽（APs）是天然和合成的抗微生物制剂，对多种微生物（包括分枝杆菌）均具有活性。我们评估了抗菌肽对 MAB 参考株和临床株的活性。我们观察到最低抑菌浓度为 1.6 至 >50μg/ml。对最有效的抗菌肽进行进一步研究表明，其可以保护粘质沙雷氏菌（AC）免受摄入的 MAB（包括 MDR MAB 菌株）的杀伤。抗菌肽为治疗耐药且治疗抵抗的 MAB 提供了一种有吸引力的潜在选择。
